Movatterモバイル変換


[0]ホーム

URL:


SG11201908280SA - "chimeric molecules and uses thereof" - Google Patents

"chimeric molecules and uses thereof"

Info

Publication number
SG11201908280SA
SG11201908280SASG11201908280SASG11201908280SASG 11201908280S ASG11201908280S ASG 11201908280SASG 11201908280S ASG11201908280S ASG 11201908280SASG 11201908280S ASG11201908280S ASG 11201908280SA
Authority
SG
Singapore
Prior art keywords
queensland
international
co7k
lucia
university
Prior art date
Application number
Inventor
Keith Chappell
Daniel Watterson
Paul Young
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=63675061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201908280S(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901152Aexternal-prioritypatent/AU2017901152A0/en
Application filed by Univ QueenslandfiledCriticalUniv Queensland
Publication of SG11201908280SApublicationCriticalpatent/SG11201908280SA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, CO7K 19/00 (2006.01) CO7K 14/165 (2006.01) KM, ML, MR, NE, SN, TD, TG). C07K 14/11 (2006.01) CO7K 14/08 (2006.01) CO7K 14/115 (2006.01) A61P 31/14 (2006.01) Published: C07K 14/15 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: PCT/AU2018/050299 (22) International Filing Date: ~~ll~~~~~~~~ 011101010VIIIOH olo olomim oviiiin mom ow (10) International Publication Number WO 2018/176103 Al (25) Filing Language: (26) Publication Language: (30) Priority Data: 2017901152 29 March 2018 (29.03.2018) English English 30 March 2017 (30.03.2017) AU (71) Applicant: THE UNIVERSITY OF QUEENSLAND [AU/AU]; The University of Queensland, St Lucia, Queens- land 4072 (AU). (72) Inventors: CHAPPELL, Keith, Joseph; The University of Queensland, St Lucia, Queensland 4072 (AU). WAT- TERSON, Daniel; The University of Queensland, St Lucia, Queensland 4072 (AU). YOUNG, Paul, Robert; The Uni- versity of Queensland, St Lucia, Queensland 4072 (AU). = (74) Agent: DAVIES COLLISON CAVE PTY LTD; 10/301 Coronation Drive, Milton, Queensland 4064 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 Cr) O 1-1 N 00 O C 1-1 1-1 (54) Title: \"CHIMERIC MOLECULES AND USES THEREOF\" (57) : Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure- stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest.
SG11201908280S2017-03-302018-03-29"chimeric molecules and uses thereof"SG11201908280SA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
AU2017901152AAU2017901152A0 (en)2017-03-30Chimeric molecules and uses thereof
PCT/AU2018/050299WO2018176103A1 (en)2017-03-302018-03-29"chimeric molecules and uses thereof"

Publications (1)

Publication NumberPublication Date
SG11201908280SAtrue SG11201908280SA (en)2019-10-30

Family

ID=63675061

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201908280SSG11201908280SA (en)2017-03-302018-03-29"chimeric molecules and uses thereof"

Country Status (15)

CountryLink
US (2)US11254712B2 (en)
EP (2)EP4512820A3 (en)
JP (2)JP7291398B2 (en)
KR (1)KR20190135017A (en)
CN (1)CN110506060B (en)
AU (1)AU2018241252B2 (en)
BR (1)BR112019019813A2 (en)
CA (1)CA3057171A1 (en)
DK (1)DK3601367T3 (en)
ES (1)ES3001108T3 (en)
IL (1)IL269534B2 (en)
MX (1)MX2019011599A (en)
PL (1)PL3601367T3 (en)
SG (1)SG11201908280SA (en)
WO (1)WO2018176103A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
RS55162B1 (en)*2007-12-242017-01-31Id Biomedical Corp Quebec RECOMBINANT RSV ANTIGENS
PL3178490T3 (en)2009-07-152022-08-01Glaxosmithkline Biologicals S.A.Rsv f protein compositions and methods for making same
LT3275892T (en)2011-05-132020-04-10Glaxosmithkline Biologicals S.A.Pre-fusion rsv f antigens
EP3752088B1 (en)2018-02-152025-03-19Wearne Digital Pte. Ltd.A platform and system for use in therapeutic procedures
EP3875110A4 (en)2018-10-252022-08-03KM Biologics Co., Ltd.Modified cmv gb protein and cmv vaccine including same
JP7454645B2 (en)*2019-07-162024-03-22ギリアード サイエンシーズ, インコーポレイテッド HIV vaccine and its production and use methods
US12419949B2 (en)*2019-07-242025-09-23Glaxosmithkline Biologicals SaModified human cytomegalovirus proteins
JP7507244B2 (en)*2020-02-052024-06-27山西錦波生物医薬股▲フェン▼有限公司 Polypeptides, methods for their preparation and uses
EP4100420A1 (en)*2020-02-062022-12-14Boehringer Ingelheim Vetmedica GmbHPolypeptides useful for detecting anti-rhabdovirus antibodies
CN112300251B (en)*2020-02-242022-04-05成都威斯克生物医药有限公司Protein and vaccine for anti SARS-CoV-2 infection
WO2021216560A2 (en)*2020-04-202021-10-28Richard AscioneVaccine compositions for sars-related coronaviruses and methods of use
BR112022022604A2 (en)*2020-05-072023-03-28Icahn School Med Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USES
JP2023528984A (en)*2020-06-102023-07-06バヴァリアン・ノルディック・アクティーゼルスカブ Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccine Against Coronavirus Disease
US20230256090A1 (en)2020-06-292023-08-17Glaxosmithkline Biologicals SaAdjuvants
IL300527A (en)*2020-08-102023-04-01Scripps Research InstCompositions and methods related to ebola virusvaccines
EP4204000A4 (en)*2020-08-262024-10-16The University of Queensland MODIFIED POLYPEPTIDES WITH IMPROVED PROPERTIES
US11175293B1 (en)2021-01-042021-11-16University Of Utah Research FoundationRapid assay for detection of SARS-CoV-2 antibodies
PE20241071A1 (en)2021-01-142024-05-13Gilead Sciences Inc HIV VACCINES AND METHODS OF USE
EP4346894A1 (en)2021-05-242024-04-10GlaxoSmithKline Biologicals S.A.Adjuvants
US20240317810A1 (en)*2021-07-152024-09-26Board Of Regents, The University Of Texas SystemPrefusion-stabilized chimeric hmpv-rsv f proteins
US20230096087A1 (en)*2021-09-242023-03-30Heinrich-Pette-Institut Leibniz-Institut für experimentelle VirologiePrefusion-stabilized herpesvirus glycoprotein-b
EP4169513A1 (en)2021-10-192023-04-26GlaxoSmithKline Biologicals S.A.Adjuvant composition comprising sting agonists
JP2025514622A (en)*2022-03-312025-05-09ザ ユニバーシティー オブ クイーンズランド Improved chimeric polypeptides and uses thereof
WO2023196945A2 (en)*2022-04-082023-10-12Icahn School Of Medicine At Mount SinaiRecombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
AU2023339047A1 (en)2022-09-092025-03-20Repligen CorporationAffinity agents
CN116789847B (en)*2023-01-132024-04-16广州医科大学附属第一医院(广州呼吸中心)Fusion proteins, virus-like particles and vaccines
WO2024186980A2 (en)*2023-03-082024-09-12Dana-Farber Cancer Institute, Inc.Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
CN119841911A (en)*2025-03-182025-04-18北京华诺泰生物医药科技有限公司Human metapneumovirus F protein mutant and application thereof
CN120248083B (en)*2025-06-052025-09-30腾讯科技(深圳)有限公司GLP-1R and GCGR double-target activating polypeptide or derivative thereof, pharmaceutically acceptable salt and application thereof

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4331647A (en)1980-03-031982-05-25Goldenberg Milton DavidTumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US7045313B1 (en)1982-11-302006-05-16The United States Of America As Represented By The Department Of Health And Human ServicesRecombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US5168062A (en)1985-01-301992-12-01University Of Iowa Research FoundationTransfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225539A (en)1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
US4946778A (en)1987-09-211990-08-07Genex CorporationSingle polypeptide chain binding molecules
US5443964A (en)1987-08-101995-08-22Duke UniversityPoxvirus insertion/expression vector
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
CA2017507C (en)1989-05-251996-11-12Gary Van NestAdjuvant formulation comprising a submicron oil droplet emulsion
GB8918616D0 (en)1989-08-151989-09-27Univ GlasgowHerpes simplex virus type 1 mutant
US5859205A (en)1989-12-211999-01-12Celltech LimitedHumanised antibodies
US5545806A (en)1990-08-291996-08-13Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)1990-08-291998-09-29Genpharm International Inc.Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en)1990-08-292000-11-15젠팜인터내셔날,인코포레이티드Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en)1990-08-291999-03-02Genpharm International Inc.Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5849572A (en)1990-10-101998-12-15Regents Of The University Of MichiganHSV-1 vector containing a lat promoter
US6410010B1 (en)1992-10-132002-06-25Board Of Regents, The University Of Texas SystemRecombinant P53 adenovirus compositions
ATE248924T1 (en)1991-05-062003-09-15Us Gov Health & Human Serv CARCINOEMBRYONAL ANTIGEN-EXPRESSING RECOMBINANT VIRUSES AND METHODS OF THEIR APPLICATION
US6407213B1 (en)1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
US5869619A (en)1991-12-131999-02-09Xoma CorporationModified antibody variable domains
US5340740A (en)1992-05-151994-08-23North Carolina State UniversityMethod of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5804413A (en)1992-07-311998-09-08University Of Pittsburgh Of The Commonwealth System Of Higher EducationHerpes simplex virus strains for gene transfer
EP1637608B1 (en)1993-10-252009-07-22CANJI, Inc.Recombinant adenoviral vector and methods of use
GB9326253D0 (en)1993-12-231994-02-23Smithkline Beecham BiologVaccines
GB9415319D0 (en)1994-07-291994-09-21Medical Res CouncilHSV viral vector
US5846782A (en)1995-11-281998-12-08Genvec, Inc.Targeting adenovirus with use of constrained peptide motifs
EP0783573B1 (en)1994-09-232005-12-21The University of British ColumbiaMethod of enhancing expression of mhc class i molecules bearing endogenous peptides
CA2201587C (en)1994-10-032002-06-25Jeffrey SchlomComposition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
FR2726003B1 (en)1994-10-212002-10-18Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
US5801030A (en)1995-09-011998-09-01Genvec, Inc.Methods and vectors for site-specific recombination
US5837511A (en)1995-10-021998-11-17Cornell Research Foundation, Inc.Non-group C adenoviral vectors
KR100643058B1 (en)1996-12-032006-11-13아브게닉스, 인크.Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE19650370A1 (en)1996-12-051998-06-10Basf Ag Flame-retardant thermoplastic molding compositions based on polyarylene ethers
US5849561A (en)1997-05-221998-12-15Cornell Research Foundation, Inc.Method for the production of non-group C adenoviral vectors
DK0985039T3 (en)1997-06-122008-06-09Novartis Int Pharm Ltd Artificial antibody polypeptides
EP1002119A1 (en)1997-07-312000-05-24University Of Pittsburgh Of The Commonwealth System Of Higher EducationTargeted hsv vectors
US6893866B1 (en)1997-11-282005-05-17The Crown In The Right Of The Queensland Department Of HealthFlavivirus expression and delivery system
US6436392B1 (en)1998-05-202002-08-20University Of Iowa Research FoundationAdeno-associated virus vectors
GB2337755B (en)1998-05-292003-10-29Secr DefenceVirus vaccine
BR9912671A (en)1998-08-072001-05-02Univ Washington Immunological antigens for herpes simplex virus and methods for their use
AT408615B (en)1998-09-152002-01-25Immuno Ag NEW INFLUENCE VIRUS VACCINE COMPOSITION
US6759237B1 (en)1998-11-052004-07-06The Trustees Of The University Of PennsylvaniaAdeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6833268B1 (en)1999-06-102004-12-21Abgenix, Inc.Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
BR0013195A (en)1999-07-092002-07-23Government Of The Us Dept Of H Production of attenuated human-bovine chimeric respiratory syncytial virus vaccines
CA2379166C (en)1999-08-092013-03-26Targeted Genetics CorporationEnhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
GB9923176D0 (en)1999-09-301999-12-01Smithkline Beecham BiologNovel composition
ES2256265T3 (en)2000-06-012006-07-16University Of North Carolina At Chapel Hill DUVICATED PARVOVIRUS VECTORS.
US7122181B2 (en)2000-12-192006-10-17Research Development FoundationLentiviral vector-mediated gene transfer and uses thereof
US7141392B2 (en)*2001-01-092006-11-28Queen Mary And Westfield CollegeLatent fusion protein
US20030133939A1 (en)2001-01-172003-07-17Genecraft, Inc.Binding domain-immunoglobulin fusion proteins
GB2372991B (en)2001-03-092004-11-17Fiocruz Fundacao Oswaldo CruzFlavivirus expression vector
JP4608210B2 (en)2001-05-312011-01-12ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Chimeric alphavirus replicon particles
AU2002322026B2 (en)2001-06-012008-03-13Acambis Inc.Chimeric flavivirus vectors
WO2004006955A1 (en)2001-07-122004-01-22Jefferson FooteSuper humanized antibodies
WO2003012054A2 (en)2001-08-022003-02-13Institut Clayton De La RechercheMethods and compositions relating to improved lentiviral vector production systems
DE60233061D1 (en)2001-09-062009-09-03Alphavax Inc ALPHAVIRUS REPLICON VECTOR SYSTEMS
WO2003029412A2 (en)2001-10-022003-04-10Institut Clayton De La RechercheRestricted expression lentivial vectors
FR2832423B1 (en)2001-11-222004-10-08Vivalis EXOGENOUS PROTEIN EXPRESSION SYSTEM IN AN AVIAN SYSTEM
JP4364643B2 (en)2001-11-302009-11-18アメリカ合衆国 Peptide agonists of prostate specific antigen and uses thereof
ES2975413T3 (en)2001-12-172024-07-05Univ Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors that contain them and their uses
FR2836924B1 (en)2002-03-082005-01-14Vivalis AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES
US7081443B2 (en)*2002-05-212006-07-25Korea Advanced Institutes Of Science And Technology (Kaist)Chimeric comp-ang1 molecule
WO2004075861A2 (en)2003-02-262004-09-10Children's Hospital, Inc.Recombinant adeno-associated virus production
US7186699B2 (en)2003-06-032007-03-06Cell Genesys, Inc.Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1486567A1 (en)2003-06-112004-12-15Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsImproved adeno-associated virus (AAV) vector for gene therapy
DK1648998T3 (en)2003-07-182015-01-05Amgen Inc Specific binding agents for hepatocyte growth factor
EP1528101A1 (en)2003-11-032005-05-04ProBioGen AGImmortalized avian cell lines for virus production
US7550296B2 (en)2004-12-012009-06-23Bayer Schering Pharma AgGeneration of replication competent viruses for therapeutic use
EP2573185A3 (en)2005-02-162013-06-05Lentigen CorporationLentiviral vectors and their use
CA2609276A1 (en)2005-05-232006-11-30De-Chu C. TangRapid production of adenovirus-free recombinant adenovirus vectors
AR054822A1 (en)2005-07-072007-07-18Sanofi Pasteur ADMISSION IMMUNE EMULSION
WO2007047706A2 (en)2005-10-172007-04-26Children's HospitalMethods and compositions for regulating gene expression
BRPI0504945B8 (en)2005-10-312022-08-02Fundacao Oswaldo Cruz METHOD FOR PRODUCTION OF RECOMBINANT FLAVIVIRUS CONTAINING NUCLEOTIDE SEQUENCES ENCODING A HETEROLOGOUS PROTEIN, DNA CONSTRUCT, FLAVIVIRUS, AND, VACCINE COMPOSITION TO IMMUNIZE AGAINST FLAVIVIRUS AND/OR OTHER PATHOGENS.
US20070249043A1 (en)2005-12-122007-10-25Mayall Timothy PAdenoviral expression vectors
CA2659592C (en)2006-07-142016-10-04Konstantin V. PugachevConstruction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
EP2117588A4 (en)2007-02-092011-05-04Sanofi Pasteur Biologics CoViral vectors and methods of use
BRPI0813194B8 (en)2007-08-032021-05-25Centre Nat Rech Scient kit, lentiviral vector particles, composition of plasmid vectors, chimeric hiv-1 derived antigen, vsv-g envelope protein, nucleic acid molecules, immunogenic composition and use of a lentiviral vector
WO2009114207A2 (en)2008-03-142009-09-17Sanofi Pasteur Biologics Co.Replication-defective flavivirus vaccines and vaccine vectors
WO2010033722A2 (en)2008-09-172010-03-25Isogenis, Inc.Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
CA2749558C (en)2008-12-082019-01-15Complix NvSingle-chain antiparallel coiled coil proteins
HUE029037T2 (en)*2008-12-092017-01-30Novavax Inc Modified RSV F proteins and methods of application
US20120128713A1 (en)2009-03-162012-05-24Sanofi Pasteur LimitedReplication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
US8679837B2 (en)2009-04-022014-03-25University Of Florida Research Foundation, Inc.Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
PL3178490T3 (en)2009-07-152022-08-01Glaxosmithkline Biologicals S.A.Rsv f protein compositions and methods for making same
CA2781519A1 (en)*2009-09-162011-03-24Genentech, Inc.Coiled coil and/or tether containing protein complexes and uses thereof
EP2486137B1 (en)2009-10-052018-05-30Ya-Fang MeiReplication-competent ad11p based viral vectors
US8927514B2 (en)2010-04-302015-01-06City Of HopeRecombinant adeno-associated vectors for targeted treatment
US20120294889A1 (en)2010-11-122012-11-22Paxvax, Inc.Chimeric Flavivirus Vaccines
ES2685611T3 (en)2011-02-142018-10-10The Children's Hospital Of Philadelphia Enhanced VAA8 vector with increased functional activity and methods of use
WO2012145509A2 (en)2011-04-192012-10-26The Research Foundation Of State University Of New YorkAdeno-associated-virus rep sequences, vectors, and viruses
LT3275892T (en)*2011-05-132020-04-10Glaxosmithkline Biologicals S.A.Pre-fusion rsv f antigens
CA2849822C (en)2011-09-232021-05-11Gary J. Nabel, M.D.Novel influenza hemagglutinin protein-based vaccines
US9506041B2 (en)2012-03-262016-11-29The United States Of America, As Represented By The Secretary, Dept. Of Health And Human ServicesDelivery of packaged RNA to mammalian cells
ES2862912T3 (en)2012-04-182021-10-08Childrens Hospital Philadelphia Composition and procedures for high-efficiency gene transfer using AAV capsid variants
US20140037680A1 (en)2012-08-062014-02-06Glaxosmithkline Biologicals, S.A.Novel method
JP2015529466A (en)2012-09-142015-10-08ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Lentiviral vector for stem cell gene therapy of sickle cell disease
SG11201502221WA (en)2012-09-212015-05-28Agency Science Tech & ResNovel attenuated dengue virus strains for vaccine application
KR20150085843A (en)*2012-11-202015-07-24글락소스미스클라인 바이오로지칼즈 에스.에이.Rsv f prefusion trimers
US9624510B2 (en)2013-03-012017-04-18The Wistar InstituteAdenoviral vectors comprising partial deletions of E3
US9060975B2 (en)*2013-03-142015-06-23Mucosis BvHeat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US20140271708A1 (en)2013-03-152014-09-18Merial LimitedNovel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G
US20160193322A1 (en)2013-08-052016-07-07Glaxosmithkline Biologicals S.A.Combination immunogenic compositions
EP2974739A1 (en)2014-07-152016-01-20Novartis AGRSVF trimerization domains
KR20190045213A (en)*2016-08-112019-05-02더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 Immune-modulating compounds
JP2025514622A (en)2022-03-312025-05-09ザ ユニバーシティー オブ クイーンズランド Improved chimeric polypeptides and uses thereof

Also Published As

Publication numberPublication date
EP3601367B1 (en)2024-10-09
EP3601367A1 (en)2020-02-05
WO2018176103A1 (en)2018-10-04
MX2019011599A (en)2019-12-19
IL269534B2 (en)2025-01-01
AU2018241252B2 (en)2024-09-19
EP4512820A2 (en)2025-02-26
JP7291398B2 (en)2023-06-15
US11254712B2 (en)2022-02-22
DK3601367T3 (en)2025-01-13
IL269534A (en)2019-11-28
IL269534B1 (en)2024-09-01
US12116386B2 (en)2024-10-15
US20200040042A1 (en)2020-02-06
US20220127309A1 (en)2022-04-28
CN110506060B (en)2024-05-07
PL3601367T3 (en)2025-03-31
EP3601367A4 (en)2020-09-16
JP2023071901A (en)2023-05-23
JP2020515272A (en)2020-05-28
EP4512820A3 (en)2025-05-21
CA3057171A1 (en)2018-10-04
BR112019019813A2 (en)2020-04-22
ES3001108T3 (en)2025-03-04
AU2018241252A1 (en)2019-10-03
KR20190135017A (en)2019-12-05
CN110506060A (en)2019-11-26

Similar Documents

PublicationPublication DateTitle
SG11201908280SA (en)"chimeric molecules and uses thereof"
SG11201907769XA (en)Cd80 variant immunomodulatory proteins and uses thereof
SG11201807279QA (en)Binding proteins and methods of use thereof
SG11201808783XA (en)Cd80 variant immunomodulatory proteins and uses thereof
SG11201810179RA (en)Novel crispr enzymes and systems
SG11201903089RA (en)Aav delivery of nucleobase editors
SG11201803593QA (en)Engineered nucleic-acid targeting nucleic acids
SG11201810003UA (en)Using programmable dna binding proteins to enhance targeted genome modification
SG11201807252QA (en)Anti-lag-3 antibodies
SG11201903012RA (en)Anti-c1s antibodies and methods of use thereof
SG11201806398YA (en)Optimized factor viii genes
SG11201803958WA (en)Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201807912SA (en)Vaccine against rsv
SG11201900138TA (en)Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201809912UA (en)Hybrid carriers for nucleic acid cargo
SG11201907298WA (en)Methods and compositions for gene transfer across the vasculature
SG11201810933QA (en)Anti-c5 antibodies and uses thereof
SG11201810048VA (en)Tri-segmented pichinde viruses as vaccine vectors
SG11201901066UA (en)Novel alkaline stable immunoglobulin-binding proteins
SG11201900201YA (en)Methods for quantitating individual antibodies from a mixture
SG11201808457PA (en)Icos ligand variant immunomodulatory proteins and uses thereof
SG11201805493YA (en)Binding members with altered diversity scaffold domains
SG11201804713VA (en)TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
SG11201407866XA (en)Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201809374VA (en)Cd40l-fc fusion polypeptides and methods of use thereof

[8]ページ先頭

©2009-2025 Movatter.jp